PE20240928A1 - Derivados de triazina y su uso en el tratamiento del cancer - Google Patents
Derivados de triazina y su uso en el tratamiento del cancerInfo
- Publication number
- PE20240928A1 PE20240928A1 PE2023003133A PE2023003133A PE20240928A1 PE 20240928 A1 PE20240928 A1 PE 20240928A1 PE 2023003133 A PE2023003133 A PE 2023003133A PE 2023003133 A PE2023003133 A PE 2023003133A PE 20240928 A1 PE20240928 A1 PE 20240928A1
- Authority
- PE
- Peru
- Prior art keywords
- halo
- alkyl
- compounds
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invencion se refiere a compuestos que tienen la formula general lb, una composicion que incluye los compuestos y metodos para usar los compuestos en el tratamiento del cancer. En particular, la invencion se refiere a compuestos de formula Ib en donde R1 es H, halo, alquilo, entre otros; R5 es H; o R1 y R5, y los atomos a los que estan unidos, forman: o un anillo de heterociclo de 4-6 miembros que comprende un unico heteroatomo de O o un anillo de cicloalquilo de 3-6 miembros, opcionalmente sustituido con uno o dos sustituyentes seleccionados independientemente de halo o alquilo; R2 es H, halo, alquilo, haloalquilo, entre otros; R3 es H, alquilo, haloalquilo o cicloalquilo opcionalmente sustituido con halo; Z es -O-, -NH- o -NHCH2-; R4 es un anillo de heterociclo o cicloalquilo opcionalmente sustituido con 1 a 2 o 1 a 3 sustituyentes respectivamente seleccionados independientemente de halo, alquilo, haloalquilo, entre otros.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21177660 | 2021-06-04 | ||
| EP21188639 | 2021-07-30 | ||
| EP21215875 | 2021-12-20 | ||
| PCT/EP2022/064995 WO2022253936A1 (en) | 2021-06-04 | 2022-06-02 | Triazine derivatives and their use in the treatment of cancer. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240928A1 true PE20240928A1 (es) | 2024-04-30 |
Family
ID=82115763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023003133A PE20240928A1 (es) | 2021-06-04 | 2022-06-02 | Derivados de triazina y su uso en el tratamiento del cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20240132471A1 (es) |
| EP (1) | EP4347571A1 (es) |
| JP (2) | JP7705963B2 (es) |
| KR (1) | KR20240019083A (es) |
| AR (1) | AR126053A1 (es) |
| AU (1) | AU2022287224A1 (es) |
| BR (1) | BR112023025318A2 (es) |
| CA (1) | CA3216026A1 (es) |
| CL (1) | CL2023003491A1 (es) |
| CO (1) | CO2023016212A2 (es) |
| CR (1) | CR20230566A (es) |
| IL (1) | IL307201A (es) |
| MX (1) | MX2023013998A (es) |
| PE (1) | PE20240928A1 (es) |
| TW (1) | TW202313577A (es) |
| WO (1) | WO2022253936A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| EP4345097A4 (en) * | 2021-04-28 | 2025-04-23 | Astellas Pharma Inc. | SUBSTITUTED TRIAZINE COMPOUND |
| TW202327604A (zh) * | 2022-01-07 | 2023-07-16 | 大陸商藥捷安康(南京)科技股份有限公司 | Ｎｌｒｐ３發炎小體抑制劑及其應用 |
| JP2025523930A (ja) * | 2022-07-21 | 2025-07-25 | エフ． ホフマン－ラ ロシュ アーゲー | Ｎｌｒｐ３阻害剤 |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| CN121045190A (zh) * | 2022-11-04 | 2025-12-02 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| EP4630417A1 (en) * | 2022-12-07 | 2025-10-15 | F. Hoffmann-La Roche AG | Novel compounds as modulators of nlrp3 inhibition |
| AU2024241125A1 (en) * | 2023-03-20 | 2025-11-06 | Insilico Medicine Ip Limited | Nlrp3 inflammasome inhibitors and uses thereof |
| WO2024193699A1 (zh) * | 2023-03-23 | 2024-09-26 | 成都赜灵生物医药科技有限公司 | 三嗪类化合物及其用途 |
| CN121039134A (zh) * | 2023-04-19 | 2025-11-28 | 豪夫迈·罗氏有限公司 | 5-[5-(2-羟基苯基)噁唑并[4,5-b]吡啶-2-基]哌啶-2-酮衍生物作为nlpr3抑制剂用于治疗炎性疾病 |
| AU2024258000A1 (en) * | 2023-04-19 | 2025-08-14 | F. Hoffmann-La Roche Ag | Oxazolo[4,5-b]pyrazine and oxazolo[4,5-b]pyridine derivatives as nlrp3 inhibitors for the treatment of e.g. inflammatory diseases |
| TW202502344A (zh) | 2023-06-02 | 2025-01-16 | 美商默沙東有限責任公司 | 作為nod樣受體蛋白3抑制劑之5,6不飽和雙環雜環 |
| WO2025026882A1 (en) * | 2023-07-28 | 2025-02-06 | F. Hoffmann-La Roche Ag | Novel compounds |
| WO2025046419A1 (ko) * | 2023-08-25 | 2025-03-06 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025252772A1 (en) * | 2024-06-06 | 2025-12-11 | F. Hoffmann-La Roche Ag | Triazine derivatives |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020003014A2 (pt) | 2017-08-15 | 2020-07-28 | Inflazome Limited | sulfonilureias e sulfoniltioureias como inibidores de vnlrp3 |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| AU2019309727B2 (en) | 2018-07-25 | 2021-12-23 | Novartis Ag | NLRP3 inflammasome inhibitors |
| CN114007614A (zh) * | 2019-02-04 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| CN115461120A (zh) | 2020-01-22 | 2022-12-09 | 豪夫迈·罗氏有限公司 | 作为nlrp3调节剂的磺酰亚胺酰胺化合物 |
| AR121669A1 (es) | 2020-03-27 | 2022-06-29 | Astellas Pharma Inc | Compuesto de piridazina sustituida |
| US20240391895A1 (en) | 2020-12-25 | 2024-11-28 | Tuojie Biotech (Shanghai) Co., Ltd. | Pyridazine-containing compound and medicinal use thereof |
| CN116867769A (zh) | 2021-02-08 | 2023-10-10 | 南京明德新药研发有限公司 | 取代的哒嗪苯酚类衍生物 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| EP4345097A4 (en) | 2021-04-28 | 2025-04-23 | Astellas Pharma Inc. | SUBSTITUTED TRIAZINE COMPOUND |
| US20240294542A1 (en) | 2021-06-05 | 2024-09-05 | Transthera Sciences (Nanjing), Inc. | Nlrp3 inflammasome inhibitor and application thereof |
| US11970463B2 (en) | 2021-07-02 | 2024-04-30 | Astrazeneca Ab | Compounds and their use |
| WO2023028536A1 (en) | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
| US20250002470A1 (en) | 2021-10-22 | 2025-01-02 | Zhejiang Aixplorer Biotech Co., Ltd. | Nitrogen-containing compound, preparation method therefor and application thereof |
| TW202327604A (zh) | 2022-01-07 | 2023-07-16 | 大陸商藥捷安康(南京)科技股份有限公司 | Ｎｌｒｐ３發炎小體抑制劑及其應用 |
| AU2023238121A1 (en) | 2022-03-25 | 2024-10-10 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives |
| EP4610258A1 (en) | 2022-10-26 | 2025-09-03 | Tenvie Therapeutics, Inc. | Fused pyridazine derivative |
| CN115621720A (zh) * | 2022-10-27 | 2023-01-17 | 永道射频技术股份有限公司 | 一种应用于rfid读写器的全息超材料阵列天线 |
| CN121045190A (zh) | 2022-11-04 | 2025-12-02 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| UY40587A (es) | 2022-12-28 | 2024-07-31 | Astrazeneca Ab | Inhibidores del inflamasoma nlrp3 |
| WO2024169858A1 (zh) | 2023-02-17 | 2024-08-22 | 成都赜灵生物医药科技有限公司 | 六元氮杂环类化合物及其用途 |
-
2022
- 2022-06-02 IL IL307201A patent/IL307201A/en unknown
- 2022-06-02 CA CA3216026A patent/CA3216026A1/en active Pending
- 2022-06-02 BR BR112023025318A patent/BR112023025318A2/pt unknown
- 2022-06-02 CR CR20230566A patent/CR20230566A/es unknown
- 2022-06-02 MX MX2023013998A patent/MX2023013998A/es unknown
- 2022-06-02 PE PE2023003133A patent/PE20240928A1/es unknown
- 2022-06-02 TW TW111120574A patent/TW202313577A/zh unknown
- 2022-06-02 WO PCT/EP2022/064995 patent/WO2022253936A1/en not_active Ceased
- 2022-06-02 EP EP22731614.8A patent/EP4347571A1/en active Pending
- 2022-06-02 JP JP2023572751A patent/JP7705963B2/ja active Active
- 2022-06-02 KR KR1020237039328A patent/KR20240019083A/ko active Pending
- 2022-06-02 AR ARP220101456A patent/AR126053A1/es unknown
- 2022-06-02 AU AU2022287224A patent/AU2022287224A1/en active Pending
-
2023
- 2023-11-23 CL CL2023003491A patent/CL2023003491A1/es unknown
- 2023-11-29 CO CONC2023/0016212A patent/CO2023016212A2/es unknown
- 2023-11-30 US US18/524,678 patent/US20240132471A1/en not_active Abandoned
-
2025
- 2025-02-25 US US19/063,141 patent/US12421209B2/en active Active
- 2025-03-26 JP JP2025051003A patent/JP2025098157A/ja active Pending
- 2025-05-16 US US19/210,925 patent/US20250276958A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023013998A (es) | 2023-12-11 |
| CR20230566A (es) | 2024-01-22 |
| JP2025098157A (ja) | 2025-07-01 |
| US20250197370A1 (en) | 2025-06-19 |
| KR20240019083A (ko) | 2024-02-14 |
| TW202313577A (zh) | 2023-04-01 |
| AR126053A1 (es) | 2023-09-06 |
| IL307201A (en) | 2023-11-01 |
| EP4347571A1 (en) | 2024-04-10 |
| CA3216026A1 (en) | 2022-12-08 |
| US20240132471A1 (en) | 2024-04-25 |
| JP7705963B2 (ja) | 2025-07-10 |
| BR112023025318A2 (pt) | 2024-02-27 |
| AU2022287224A1 (en) | 2023-09-21 |
| JP2024522494A (ja) | 2024-06-21 |
| US12421209B2 (en) | 2025-09-23 |
| WO2022253936A1 (en) | 2022-12-08 |
| US20250276958A1 (en) | 2025-09-04 |
| CL2023003491A1 (es) | 2024-05-24 |
| CO2023016212A2 (es) | 2023-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240928A1 (es) | Derivados de triazina y su uso en el tratamiento del cancer | |
| AR112797A1 (es) | Inhibidores de kras g12c y métodos para utilizarlos | |
| AR123048A2 (es) | Moduladores de p2x7 | |
| MX2019011679A (es) | Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular. | |
| UY37854A (es) | Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos | |
| AR116109A1 (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
| CO6251294A2 (es) | Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazol4,5-b piridin-5-amina y su uso para el tratamiento del cancer | |
| AR108356A1 (es) | Derivados aromáticos de sulfonamida | |
| PE20211781A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
| ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
| ECSP22027871A (es) | COMPUESTOS HETEROC?CLICOS DE ARILMETILENO COMO BLOQUEADORES DEL CANAL SHAKER DE POTASIO Kv1.3 | |
| AR108778A1 (es) | Compuestos antibacterianos | |
| CL2024001620A1 (es) | Inhibidores del sarcómero cardíaco | |
| CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
| CL2025001372A1 (es) | Derivados de triazinona como inhibidores de nlrp3. | |
| PE20171335A1 (es) | Inhibidores de gingipaina de lisina | |
| CL2020003380A1 (es) | Compuestos que aumentan la actividad del proteosoma. | |
| AR083861A1 (es) | OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| MX2024012471A (es) | Inhibidores de cinasas dependientes de ciclina 9 (cdk9) | |
| CO2025003256A2 (es) | Derivados novedosos deuterados de pirimidin-2-il sulfonamida | |
| CL2025000126A1 (es) | Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina. | |
| CL2025000125A1 (es) | Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina. | |
| CL2023003921A1 (es) | Inhibidores de transglutaminasas | |
| UY37641A (es) | Compuestos de isoxazol carboxamida y usos de los mismos |